NDT Advance Access published online on January 23, 2006
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfk088
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Cardiovascular Division, Toujinkai Hospital, Kyoto, Japan
* To whom correspondence should be addressed. Background. Success of coronary stenting is limited by in-stent restenosis. We aimed to determine whether circulating levels of the cytokines, which have anti-inflammatory properties such as adiponectin or interleukin-10, could be associated with the occurrence of coronary in-stent restenosis in patients with end-stage renal disease (ESRD). Methods. We enrolled 71 consecutive ESRD patients undergoing haemodialysis (mean age: 64.9±8.9 years; 19 women, 52 men; mean haemodialysis duration: 78.2±87.5 months), who received stenting for a single coronary lesion. Plasma concentrations of adiponectin and IL-10 were measured within one week before coronary stenting. Results. Of the 71 patients who had received stenting, in-stent restenosis occurred in 37 patients (52.1%) within 6 months after stenting. In univariate logistic analysis, the homeostasis model assessment index of insulin resistance, blood haemoglobin, serum concentrations of high density lipoprotein-cholesterol or triglycerides and plasma concentrations of insulin or adiponectin were significantly associated with coronary in-stent restenosis. In a multiple logistic regression analysis among these variables, however, only the plasma adiponectin concentration was associated with the coronary in-stent restenosis: the odds ratio of the increase in 1 µg/ml of plasma adiponectin concentration for having restenosis was 0.651 (P = 0.001, 95% confidence interval: 0.506-0.839). Patients with restenosis had lower plasma adiponectin concentrations than those without [6.2±2.2 µg/ml (2.1-10.4 µg/ml; n = 37) vs 27.2±10.8 µg/ml (17.9-79.8 µg/ml; n = 34); P = 0.0001]. Conclusions. Circulating adiponectin concentrations may be associated with the occurrence of coronary in-stent restenosis in ESRD patients undergoing maintenance haemodialysis.
Received January 16, 2005
Accepted January 3, 2006
Original Article
Association of the circulating adiponectin concentration with coronary in-stent restenosis in haemodialysis patients
Masato Nishimura 1 *,
Tetsuya Hashimoto 2,
Hiroyuki Kobayashi 2,
Satoru Yamazaki 2,
Koji Okino 3,
Hiroshi Fujita 4,
Naoto Inoue 3,
Hakuo Takahashi 5,
and
Toshihiko Ono 2
2 Division of Urology, Toujinkai Hospital, Kyoto, Japan
3 Division of Surgery, Toujinkai Hospital, Kyoto, Japan
4 Department of Interventional Cardiology, Kyoto Second Red Cross Hospital, Kyoto, Japan
5 Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, Moriguchi, Japan
Masato Nishimura, E-mail: mnishimura{at}tea.ocn.ne.jp
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Bacchetta, S. Boutroy, F. Guebre-Egziabher, L. Juillard, J. Drai, S. Pelletier, M. Richard, A. Charrie, M. C. Carlier, R. Chapurlat, et al. The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3120 - 3125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Szmitko, H. Teoh, D. J. Stewart, and S. Verma Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1655 - H1663. [Abstract] [Full Text] [PDF]
|
|